| LAD (mm) | LAVmax (ml) | LAVmin (ml) | LAEF (%) | LVESD (mm) | LVEDD(mm) | LVEF (%) |
---|---|---|---|---|---|---|---|
Sham group | Â | Â | Â | Â | Â | Â | Â |
 Baseline | 9.73 ± 0.69 | 0.54 ± 0.08 | 0.27 ± 0.05 | 48.82 ± 4.48 | 8.46 ± 0.99 | 13.68 ± 1.77 | 72.20 ± 3.65 |
 4 weeks post-operation | 9.85 ± 0.61 | 0.53 ± 0.07 | 0.28 ± 0.05 | 47.59 ± 6.05 | 8.44 ± 0.91 | 13.53 ± 1.53 | 71.75 ± 2.81 |
Control group | Â | Â | Â | Â | Â | Â | Â |
 Baseline | 9.58 ± 0.62 | 0.52 ± 0.09 | 0.26 ± 0.03 | 49.42 ± 3.39 | 8.39 ± 0.88 | 13.37 ± 1.23 | 71.18 ± 4.46 |
 3 weeks after RAP | 16.02 ± 0.84*, ** | 1.94 ± 0.28*, ** | 1.40 ± 0.18*, ** | 27.77 ± 4.18*, ** | 8.77 ± 0.64 | 13.35 ± 1.28 | 67.47 ± 2.92 |
Atorvastatin group | Â | Â | Â | Â | Â | Â | Â |
 Baseline | 9.75 ± 0.56 | 0.55 ± 0.10 | 0.28 ± 0.05 | 49.31 ± 5.48 | 8.37 ± 0.94 | 13.58 ± 1.32 | 71.42 ± 3.15 |
 3 weeks after RAP | 15.53 ± 0.62*, ** | 1.78 ± 0.24*, ** | 1.29 ± 0.17*, ** | 27.32 ± 3.70*, ** | 8.78 ± 0.78 | 13.64 ± 1.22 | 68.50 ± 5.34 |